Compare OKTA & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OKTA | WST |
|---|---|---|
| Founded | 2009 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8B | 23.9B |
| IPO Year | 2017 | 2004 |
| Metric | OKTA | WST |
|---|---|---|
| Price | $195.80 | $370.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 36 | 7 |
| Target Price | $103.60 | ★ $325.86 |
| AVG Volume (30 Days) | ★ 4.3M | 377.8K |
| Earning Date | 05-26-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.30% |
| EPS Growth | ★ 2083.33 | 1.49 |
| EPS | 1.07 | ★ 4.07 |
| Revenue | ★ $2,919,000,000.00 | $2,886,900,000.00 |
| Revenue This Year | $11.27 | $6.76 |
| Revenue Next Year | $9.36 | $6.22 |
| P/E Ratio | $193.12 | ★ $91.79 |
| Revenue Growth | ★ 11.84 | 1.95 |
| 52 Week Low | $62.66 | $223.83 |
| 52 Week High | $212.50 | $386.00 |
| Indicator | OKTA | WST |
|---|---|---|
| Relative Strength Index (RSI) | 62.72 | 63.12 |
| Support Level | $72.21 | $346.45 |
| Resistance Level | N/A | $386.00 |
| Average True Range (ATR) | 9.71 | 8.67 |
| MACD | 1.54 | 2.41 |
| Stochastic Oscillator | 65.09 | 75.37 |
Okta is a cloud-native security company specializing in identity and access management. The San Francisco-based firm went public in 2017 and serves two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees, contractors, and partners to securely access its cloud-based and on-premises resources. The firm's customer offering, delivered via its Auth0 platform, allow clients to provide secure access experiences to their own end users.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.